Clinical Trial Update: Open-Label Phase III Long-Term Safety Trial of Liprotamase [Phase 3]

View source ↗

Summary

The open-label Phase III long-term safety trial of Liprotamase has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• Liprotamase (liprotamase)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 3 | Status: COMPLETED